Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia

Bone Marrow Transplantation

Volumn 28, Issue 10, 2001, Pages 951-956

  Kumar, S ^a   Chen, M G ^a   Gastineau, D A ^a   Gertz, M A ^a   Inwards, D J ^a   Lacy, M Q ^a   Tefferi, A ^a   Litzow, M R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Allogeneic; Bone marrow transplantation; Cyclosporine; Lymphocyte recovery; Prophylaxis; Relapse

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; METHOTREXATE; PREDNISONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; CONVALESCENCE; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; LEUKEMIA REMISSION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; SIBLING; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035202651     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703262     Document Type: Article

References (51)

1. Marrow transplantation for acute nonlymphoblastic leukemia in first remission
2. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia
3. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia (letter)
4. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2
5. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the de Moelle Osseuse
6. Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: The effect of FAB classification and GVHD prophylaxis
7. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission
8. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant
9. Outcome of acute leukemia relapsing after bone marrow transplantation: Utility of second transplants and adoptive immunotherapy
10. The first clinical use of donor leukocyte infusions for the treatment of leukemia relapsing after allogeneic bone marrow transplantation
11. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
12. Donor lymphocyte infusion induced molecular remission in relapse of acute myeloid leukaemia after allogeneic bone marrow transplantation
13. Sustained complete cytologic and molecular remission induced by donor leucocyte infusions alone in an acute myeloblastic leukaemia in relapse after bone marrow transplantation
14. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation
15. Non myeloablative 'mini transplants'
16. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man
17. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts
18. Graft-versus-leukemia reactions after bone marrow transplantation
19. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells
20. Graft-versus-leukaemia following allogeneic bone marrow transplantation: Emergence of cytotoxic T lymphocytes reacting to host leukaemia cells
21. Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease
22. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation
23. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow
24. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia
25. Peripheral blood T lymphocytes bearing DR antigen after bone marrow transplantation
26. Regeneration of T cell subpopulations after bone marrow transplantation: Cytomegalovirus infection and lymphoid subset imbalance
27. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia
28. Effect of GVHD on the recovery of NK cell activity and LAK precursors following BMT
29. Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation
30. Immune system reconstitution following allogeneic bone marrow transplantation in man: A multiparameter analysis
31. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors
32. T-cell subpopulations identified by monoclonal antibodies after human marrow transplantation. I. Helper-inducer and cytotoxic-suppressor subsets
33. Phenotype of recovering lymphoid cell populations after marrow transplantation
34. Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT)
35. Mechanism of cytotoxicity by natural killer (NK) cells
36. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: Single-center experience of 32 adult patients
37. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
38. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: A single center experience of 12 children
39. Lysis of autologous tumor cells by peripheral blood lymphocytes treated with interleukin 2 in patients with renal cell carcinoma
40. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission
41. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation
42. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation
43. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse
44. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
45. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow
46. Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation
47. Declining lymphocyte counts following cytomegalovirus (CMV) infection are associated with fatal CMV disease in bone marrow transplant patients
48. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes
49. The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo
50. + selected PBPC grafts, unselected PBPC grafts or BM grafts
51. + selected grafts with recipients of unmanipulated grafts